Supplementary material to article by D. Roblin et al. "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from In vitro and Tissue Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b, Randomised, Double-blind, Vehicle-controlled Clinical Trial in Patients with Psoriasis"

Table SIII.	Summary of	^e pruritus visu	al analogue	scale scores	(full analysis set)
ruore onn.	Summary Of	prarias visa	ui unuiogue	scure scores	Juli analysis self

	CT327 0.05% n=40	CT327 0.1% n=40	CT327 0.5% n=40	Vehicle $n=0$
	Mean (min, max)	Mean (min, max)	Mean (min, max)	Mean (min, max)
Baseline ^a	51.9 (0, 91)	50.6 (0, 98)	57.3 (5, 100)	43.6 (0, 100)
Week 2	29.1 (0, 91)	34.3(0, 89)	38.3 (1, 100)	30.1 (0, 100)
Week 4	26.0 (0, 100)	27.2 (0, 83)	35.6 (0, 100)	30.2 (0, 95)
Week 8	20.9 (0, 91)	26.7 (0, 80)	28.4 (0, 100)	34.3 (0, 100)
Change at Week 2 ^a	-22.8 (-66, 15)	-17.7 (-71, 22)	-20.6 (-70, 26)	-14.6 (-70, 55)
Change at Week 4 ^a	-25.9 (-68, 50)	-24.5 (-90, 39)	-23.4 (-70, 40)	-14.1 (-70, 46)
Change at Week 8ª	-31.0** (-73, 20)	-24.9 (-91, 25)	-30.8* (-95, 20)	-10.5 (-88, 71)
-	p = 0.0040	p = 0.0537	p = 0.0194	
Change at Week 2, % ^a	-43.3(-100, 42.9)	-29.5 (-100, 95.7)	-35.1 (-98.6, 50.0)	-28.3 (-100, 163.2
Change at Week 4, % ^a	-50.4 (-100, 100)	-45.3 (-100, 88.6)	-37.6 (-100, 200)	-31.7 (-100, 110.5
Change at Week 8, % ^a	-60.0 (-100, 33.3)	-47.4 (-100, 56.8)	-50.3 (-100, 80)	-20.4 (-100, 355)

^an=39 for CT327 0.1%, CT327 0.5% and vehicle groups.

p*<0.02; *p*<0.005.